查詢結果分析
相關文獻
- Denosumab治療骨鬆與腫瘤骨轉移
- 核醫藥物放射性核種治療製劑錸-188--錫-1,1氫氧亞乙基二磷酸鹽之特性研究
- Clodronate--治療乳癌的骨轉移
- 骨骼轉移的單次與分次緩和性放射治療的比較:一個前瞻性隨機試驗
- 照顧一位肺癌骨轉移之年輕女病患之護理經驗
- 癌症病人的骨轉移
- 放射性同位素治療劑錸-188-錫-1,1-羥基亞乙基二磷酸鹽之體外特性分析與生物體分佈研究
- Breast Cancer Metastasis Causing Bilateral Subtrochanteric Pathological Fractures: A Case Report
- 癌症併發骨轉移的機制
- 從「見骨頭」到「健骨頭」:淺談核醫在癌症骨轉移的應用
頁籤選單縮合
題 名 | Denosumab治療骨鬆與腫瘤骨轉移=Denosumab for Treatment of Osteoporosis and Bone Metastases |
---|---|
作 者 | 林政仁; 曾思文; | 書刊名 | 藥學雜誌 |
卷 期 | 29:2=115 2013.06[民102.06] |
頁 次 | 頁46-50 |
分類號 | 418.295 |
關鍵詞 | 停經後婦女骨質疏鬆症; 骨轉移; Denosumab; Osteoporosis; Skeletal-related events; Bone metastases; |
語 文 | 中文(Chinese) |
中文摘要 | 2010年美國食品藥物管理局 (U.S. Food and Drug Administration,FDA) 核准denosumab 注射藥用於治療骨折高風險之骨質疏鬆的停經婦女,它是一個全新機轉的藥。Denosumab 是人類 IgG2 單株抗體,會與 RANKL 結合,使得 RANKL 無法與 RANK 相互結合,進而造成蝕骨細胞之前驅細胞無法分化成成熟之蝕骨細胞,因此可降低骨質溶蝕作用並提高皮質骨及小樑骨的骨量與強度。2011年 FDA 也核准 denosumab 用於預防實體腫瘤轉移骨骼相關疾病。 |
英文摘要 | Denosumab has been approved for treating high fracture risk of osteoporosis in postmenopausal women by the U.S. Food and Drug Administration (FDA) in 2010. It is a drug of entirely new mechanism. Denosumab is a human IgG2 monoclonal antibody that inhibits the binding of receptor activation of nuclear factor kappa B ligand (RANKL) to RANK receptors located on the surface of osteoclasts and their precursor cells. This inactivation prevents the formation, function, and survival of osteoclasts, and then reduces bone resorption, allowing for growth in cortical and trabecular bone. An improvement in BMD (bone mass density) has been demonstrated with the use of denosumab. In 2011, FDA also approved denosumab for prevention of skeletal-related events in bone metastases from solid tumors. |
本系統中英文摘要資訊取自各篇刊載內容。